Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06118515 · ClinicalTrials.gov registry record · Phase 1
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
A Phase 1 study of Congenital Cytomegalovirus Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 10
- Study locations
NCT06118515 is a Phase 1 study of Congenital Cytomegalovirus Infection that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 12 participants. The trial reports 10 study locations across 10 states.
The verdict
NCT06118515, a Phase 1 study of Congenital Cytomegalovirus Infection, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase 1 single-arm open-label study of letermovir in neonates with symptomatic congenital Cytomegalovirus (CMV) disease. There will be two groups enrolled. Group 1 will be comprised of 4 subjects. Following documentation study inclusion and signing of informed consent, Group 1 subjects will receive one dose of oral letermovir (Study Day 0), using the dose bands. A full pharmacokinetics (PK) profile will then be obtained over the next 24 hours, and blood specimens will be shipped immediately to the University of Alabama at Birmingham (UAB) Pharmacokinetic Lab and processed in real time. Within = 7 days, pharmacokinetics (PK) results will be conveyed to the study site. If the Area Under the Curve (AUC24) is =100,000 ngxhr/mL (see footnote a in Table 1), the subject will initiate a 14-day course of once-daily oral letermovir at the same dose as utilized on Dose Finding Day. This duration of letermovir therapy was selected based upon our earlier observation in this population that patients with symptomatic congenital Cytomegalovirus (CMV) disease who achieve viral suppression to =2.5 log by day 14 of valganciclovir therapy and then maintain it over the next 4 months are statistically more likely to have improved hearing across the first two years of life (22). If the observed letermovir exposure of the subject is \> 100,000 ngxhr/mL, the once-daily oral letermovir dose that will be used will be adjusted down in 2.5 mg increments. Oral valganciclovir (16 mg/kg/dose BID) will begin within the first month of life, as standard of care; initiation of valganciclovir can be concomitant with or prior to initiation of the 14-day course of letermovir (but will not start before obtaining the pharmacokinetics (PK) specimens following the single dose of letermovir on the Dose Finding Day). This is similar to the intensification approach that has been evaluated in the management of patients infected with human immunodeficiency virus (23-25). The day that the 14-day course o
Conditions Studied
Interventions
- DRUG Letermovir
Study Locations (10)
Alabama
- Children's of Alabama Child Health Research Unit (CHRU) - Birmingham
District of Columbia
- Children's National Medical Center - Sheikh Zayed Campus - Infectious Disease - Washington D.C.
Georgia
- Emory University School of Medicine - Atlanta
Kentucky
- University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases - Louisville
Louisiana
- Louisiana State University Health Shreveport - Infectious Diseases - Shreveport
Minnesota
- University of Minnesota - Pediatric Infectious Disease - Minneapolis
New York
- SUNY Upstate Medical University Hospital - Pediatrics - Syracuse
Ohio
- Nationwide Children's Hosp.-Neonatology-Ctr. for Perinatal Rsrch. - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-02-19 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06118515
The ClinicalTrials.gov registry entry for NCT06118515 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Congenital Cytomegalovirus Infection appearing as the primary indexed condition, and to 1 intervention - of which Letermovir is the first listed.
NCT06118515 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Alabama, District of Columbia, Georgia.
Frequently Asked Questions
What is clinical trial NCT06118515 about?
NCT06118515 is a clinical study titled "A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus". This is a Phase 1 single-arm open-label study of letermovir in neonates with symptomatic congenital Cytomegalovirus (CMV) disease. There will be two groups enrolled. Group 1 will be comprised of 4 subjects. Following documentation study inclusion and signing of informed consent, Group 1 subjects wil...
What is the current status of trial NCT06118515?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-02-19. Estimated completion is 2026-08-31.
What conditions does trial NCT06118515 study?
This clinical trial studies the following conditions: Congenital Cytomegalovirus Infection.
What interventions are being tested in trial NCT06118515?
The interventions under investigation include: Letermovir (DRUG).
Who is sponsoring clinical trial NCT06118515?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06118515 being conducted?
This trial has 10 study locations across Alabama, District of Columbia, Georgia, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.